Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666210914113752

Prakrati Yadav, Deepak Kumar, Durga S Meena, Naresh K Midha, Gopal K Bohra, Mahendra K Garg, Abhishek H L Purohit

{"title":"Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma.","authors":"Prakrati Yadav, Deepak Kumar, Durga S Meena, Naresh K Midha, Gopal K Bohra, Mahendra K Garg, Abhishek H L Purohit","doi":"10.2174/1871529X21666210914113752","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits.Case description: We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.Conclusion: There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 3","pages":"206-209"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X21666210914113752","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits.

Case description: We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.

Conclusion: There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.

查看原文本刊更多论文

COVID-19患者出院后预防性抗凝:一个临床困境。

背景:2019冠状病毒病大流行给全球卫生保健系统造成了巨大损失。除了大流行之外，人们还担心康复患者的COVID-19后并发症。据报道，血栓栓塞(TE)是COVID-19康复患者的致命并发症。在出院后TE预防及其长期效益方面仍然存在很大的困境。病例描述:我们报告了3例COVID-19后合并两种疾病相关并发症以及出院后抗凝治疗的病例。第一个病例是一名60岁的男性，他患上了Covid-19肺炎(中度疾病)，初步好转后使用利伐沙班出院。3周后，患者因下消化道出血再次入院。另外2例在2-3个月内(COVID-19肺炎康复后)发生肺血栓栓塞。这两名患者均未使用抗凝剂预防TE。结论:迫切需要制定有效的COVID-19患者出院后TE预防指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.